Highlights

  • Macquarie maintains an Outperform rating on Pro Medicus with a target price of A$221
  • The company secured more than A$190 million in new contract announcements and renewals during recent months
  • First-half FY2026 Revenue increased 28.4%, while Underlying Profit before tax rose 29.7%

Pro Medicus Limited (ASX:PME) remains one of Australia's most closely followed healthcare technology companies. Despite delivering another period of revenue growth, expanding profitability, and securing multiple major healthcare contracts in North America, the stock remains more than 43% below levels seen a year ago.

The disconnect between operational performance and share price movement has prompted investors to reassess the company. While market sentiment toward high-growth technology stocks has fluctuated over the past year, Pro Medicus continues to report growing Demand for its enterprise imaging solutions and an expanding contract pipeline.

With broker support remaining positive and several major customer wins announced in recent months, investors are evaluating whether the company's recent weakness warrants renewed attention.

Broker Outlook Remains Positive

Macquarie continues to maintain an Outperform rating on Pro Medicus with a target price of A$221.

The broker's view reflects confidence in the company's Long-term Growth prospects, Recurring Revenue model, and ability to continue winning contracts within the highly competitive healthcare imaging software market.

Professional investors often pay close attention to broker sentiment when evaluating healthcare technology companies because future growth depends heavily on contract wins, implementation success, and customer retention.

Macquarie's continued positive stance suggests analysts remain encouraged by the company's operational momentum despite recent share price pressure.

Share Price Weakness Contrasts With Business Performance

The decline of more than 43% over the past year has attracted considerable market attention.

However, the company's recent operational performance presents a different picture.

Rather than experiencing a slowdown in customer demand, Pro Medicus has continued to secure large-scale contracts, expand relationships with existing healthcare systems, and grow its financial results.

This divergence between business performance and market valuation has become a key talking point among investors following the stock.

The focus increasingly rests on whether the company's contract momentum and Earnings growth can continue to support its long-term growth profile.

First-Half FY2026 Results Highlight Continued Growth

Pro Medicus delivered another record financial result for the six months ended December 2025.

Revenue increased 28.4% to A$124.8 million, while underlying profit before tax rose 29.7% to A$90.7 million.

Underlying net profit reached A$67.3 million, reflecting continued growth across the company's core medical imaging software operations.

Reported net profit after tax increased significantly to A$171.2 million. However, this figure included unrealised gains associated with the company's Investment in 4DMedical and therefore does not fully reflect underlying operating performance.

Perhaps more notable was the company's ability to maintain profitability while continuing to scale.

Underlying EBIT margins improved to 73%, compared with 72% in the previous corresponding period.

Margin performance remains one of Pro Medicus' distinguishing characteristics and highlights the scalability of its software platform.

Debt-Free Balance Sheet Provides Flexibility

The company continues to operate without debt.

Cash and financial Assets reached A$221.8 million at the end of December 2025 despite Dividend payments, share Buybacks, and a strategic investment in 4DMedical.

For investors, the debt-free balance sheet provides significant flexibility.

Many software companies rely on external financing to support growth initiatives, acquisitions, or Research and Development programs. Pro Medicus, by contrast, continues to fund expansion from internally generated Cash Flow.

The balance sheet position also supports Shareholder returns through dividends and Capital management initiatives.

Contract Momentum Remains a Key Driver

One of the most important factors underpinning investor confidence is the continued flow of new contracts.

During the first half alone, Pro Medicus announced contracts with a combined minimum value exceeding A$280 million.

Major agreements included a 10-year A$170 million contract with the University of Colorado, a A$44 million contract with Advanced Radiology Management, and multiple additional contracts spanning hospitals, cancer centres, and specialist healthcare providers.

The company's contract activity has continued into 2026.

Recent announcements include:

  • A seven-year A$90 million agreement with Beth Israel Lahey Health.
  • A five-year A$37 million contract renewal with Northwestern.
  • A five-year A$23 million contract with the University of Maryland.
  • A five-year A$28 million contract renewal with Allegheny Health.
  • A seven-year A$16 million contract with TidalHealth.
  • Two contract renewals announced earlier in the year worth a minimum of A$40 million.

These wins reinforce Pro Medicus' position within the North American healthcare imaging market, which remains the company's primary growth engine.

Expansion of the Full-Stack Strategy

A recurring theme throughout recent contract announcements has been increasing adoption of the company's broader software suite.

Historically, many healthcare providers initially adopted Pro Medicus' Visage Viewer solution.

More recent contracts increasingly include multiple products, including workflow, archive, and cardiology modules.

Management has described this as a growing "full-stack" opportunity.

The expansion of customer relationships beyond a single software component can increase contract value, deepen customer integration, and create longer-term revenue opportunities.

Several recent agreements have also included the company's cardiology offering, which management believes represents an additional avenue for growth.

Cloud Adoption Continues to Accelerate

Another trend supporting the business is the increasing adoption of cloud-based healthcare infrastructure.

Management reported that all six major implementations completed during the first half were cloud-based.

Cloud deployment enables healthcare providers to access advanced imaging capabilities while reducing the need for extensive on-site infrastructure.

For Pro Medicus, the transition toward cloud environments broadens its addressable market and aligns its solutions with evolving customer preferences.

The company expects additional implementations during the second half of FY2026, with several major projects scheduled to go live over coming months.

As implementations become operational, revenue contributions typically increase over time.

Market Position Remains Differentiated

Chief Executive Officer Dr Sam Hupert has repeatedly highlighted what management views as a unique competitive position.

The company serves a wide range of healthcare customers, from specialised imaging providers to some of the largest integrated healthcare networks and academic medical centres in the United States.

This broad applicability allows Pro Medicus to pursue opportunities across multiple segments of the diagnostic imaging market.

The company's Visage 7 platform continues to be a key differentiator due to its speed, scalability, and ability to operate across public and private cloud environments.

As healthcare organisations increasingly prioritise workflow efficiency and imaging accessibility, these capabilities remain central to customer decision-making.

Share Buybacks Reflect Management Confidence

Another noteworthy development has been the company's continued capital management activity.

Pro Medicus announced share buyback initiatives during the year while simultaneously maintaining dividend payments.

Share buybacks can indicate management's confidence in the company's long-term prospects and financial position.

Combined with a fully franked Interim Dividend of 32 cents per share, the capital management approach demonstrates the company's ability to return capital while continuing to invest in future growth opportunities.

Looking Ahead

Management remains optimistic regarding future opportunities.

The company expects several major customer implementations to be completed before the end of FY2026, including additional Trinity Health cohorts.

Revenue from these implementations should progressively contribute to future reporting periods.

Management also described the current sales pipeline as very strong, with significant lead generation resulting from industry engagement activities, including the RSNA conference in the United States.

The ability to convert this pipeline into additional contracts will remain a central focus for investors.

Conclusion

Despite a substantial share price decline over the past year, Pro Medicus continues to deliver many of the operational characteristics that have historically attracted investors. Revenue growth, expanding profitability, a debt-free balance sheet, growing cloud adoption, and a steady stream of large contract wins continue to support the company's long-term growth narrative. Macquarie's Outperform rating reflects confidence in these fundamentals, while recent customer wins demonstrate ongoing demand for the company's imaging software platform. As additional implementations come online and recently announced contracts begin contributing revenue, Pro Medicus remains a closely watched healthcare technology company for investors monitoring the medical imaging sector.